Dear Shane Le Brun

Thank you for your request for official information, received by the
Ministry of Health on 26 April 2016, requesting:

I would like to know the Geographic Distribution of the approvals Sativex
prescriptions since its availability in NZ several years ago.

1.  Can I please have a breakdown for all prescriptions by Region/DHB or
whatever unit is most convenient based on your recording,  

2.  Can I also have a breakdown by region of the approvals for "Off-Label"
that is conditions other than Multiple Sclerosis related Spasticity,

3. Secondary to this I would also like to see a breakdown of what
conditions renewals of Sativex Prescriptions have been approved for, since
Sativex has become available.

This information is in the public interest as we seek to demonstrate
regional variances in the availability of Sativex due to the lack of
specialists or secondary factors relating to the willingness of
specialists to perscribe Sativex.    Question 3 is in the public interest
as we seek to demonstrate what conditions have had sustained therapeutic
benefit from Sativex.

Your request has been received and logged.

As required under the Official Information Act 1982, the Ministry will
respond to your request within 20 working days. You should receive a
response on or before 24 May 2016

If a large amount of information has been requested or if the Ministry
needs to consult in order to make a decision, we may need to extend this
date (this is provided for in Section 15A of the Act).  We will advise you
if such an extension is necessary.

The Ministry's reference number for your request is: H201601614

Kind regards,

Ashley Goodwin l Support Officer
[MOH request email]
Government Relations l Office of the Director General

[1]http://www.health.govt.nz
****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

--------------------------------------------------------------------------

This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway

--------------------------------------------------------------------------

References

Visible links
1. http://www.health.govt.nz/

hide quoted sections

Kia ora,

Please find attached the response to your recent request for information.

Kind regards,

Chris Fletcher l OIA Co-ordinator
[MOH request email]
Government Relations l Ministerial, Executive and Government Services l
Office of the Director General

[1]http://www.health.govt.nz

From:        Shane Le Brun <[FOI #3927 email]>
To:        OIA requests at MOH <[MOH request email]>,
Date:        26/04/2016 12:23 p.m.
Subject:        Official Information Act request - Sativex - Geographic
distribution

--------------------------------------------------------------------------

Dear Ministry of Health,

I would like to know the Geographic Distribution of the approvals Sativex
prescriptions since its availability in NZ several years ago.

1.  Can I please have a breakdown for all prescriptions by Region/DHB or
whatever unit is most convenient based on your recording,  

2.  Can I also have a breakdown by region of the approvals for "Off-Label"
that is conditions other than Multiple Sclerosis related Spasticity,

3. Secondary to this I would also like to see a breakdown of what
conditions renewals of Sativex Prescriptions have been approved for, since
Sativex has become available.

This information is in the public interest as we seek to demonstrate
regional variances in the availability of Sativex due to the lack of
specialists or secondary factors relating to the willingness of
specialists to perscribe Sativex.    Question 3 is in the public interest
as we seek to demonstrate what conditions have had sustained therapeutic
benefit from Sativex.

Yours faithfully,

Shane Le Brun

-------------------------------------------------------------------

This is an OIA request done via the FYI website.

Please do not send progress updates as PDF files.

Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
[2]https://fyi.org.nz/help/officers

If you find this service useful as an OIA officer, please ask your web
manager to link to us from your organisation's OIA page.

-------------------------------------------------------------------
****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

--------------------------------------------------------------------------

This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway

--------------------------------------------------------------------------

References

Visible links
1. http://www.health.govt.nz/
2. https://fyi.org.nz/help/officers

hide quoted sections